Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.46 |
| ▸ | DDX3X | O00571 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690365 | 0.89 | MAPT (0.59) | GAAMAPTGFERGPR35ALDH1A1 | |
| SCHEMBL8885278 | 0.85 | ALDH1A1 (0.52) | GAAMAPTGFERALDH1A1DDX3X | |
| SCHEMBL8532903 | 0.84 | ALDH1A1 (0.67) | MAPTALDH1A1POLBNR4A1RAB9A | |
| SCHEMBL1487964 | 0.82 | ALDH1A1 (0.66) | MAPTALDH1A1POLBNR4A1RAB9A | |
| SCHEMBL697192 | 0.82 | GPR35 (0.55) | MAPTGPR35ALDH1A1KCNK3KCNK9 | |
| SCHEMBL20714982 | 0.80 | CYP1A2 (0.43) | GPR35ALDH1A1KCNK3KCNK9DDX3X | |
| SCHEMBL20057531 | 0.80 | CYP1A2 (0.67) | GAAMAPTALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL22699676 | 0.80 | MAPT (0.50) | GAAMAPTGFERGPR35ALDH1A1 | |
| SCHEMBL16488795 | 0.80 | MEN1 (0.51) | MAPTGPR35ALDH1A1DDX3XPOLB | |
| SCHEMBL166848 | 0.80 | HSD17B10 (0.69) | GAAALDH1A1KCNK3KCNK9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
| EP-3180326-B1 | BENZODIAZEPINE DERIVATIVES AS CCK2/GASTRIN RECEPTOR ANTAGONISTS | TRIO MEDICINES LTD (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9618867-B2 | Pigment dispersion and toner | CANON KABUSHIKI KAISHA (JP) | 2017-04-11 | — | — | US | disclosed |
| US-20160246200-A1 | PIGMENT DISPERSION AND TONER | CANON KABUSHIKI KAISHA (JP) | 2016-08-25 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| CN-1075717-A | Benzodiazepine * derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-09-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | GAA 313/4885MAPT 2243/4885GFER 3366/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | GAA 2400/4885MAPT 4679/4885GFER 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.